This company is no longer active
BOTHE Stock Overview
Bone Therapeutics SA, a biotechnology company, engages in the development of cell therapy products for orthopedics and bone diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Bone Therapeutics SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.14 |
| 52 Week High | €1.43 |
| 52 Week Low | €0.12 |
| Beta | 0.30 |
| 1 Month Change | -30.39% |
| 3 Month Change | -41.83% |
| 1 Year Change | -89.97% |
| 3 Year Change | -95.71% |
| 5 Year Change | -98.55% |
| Change since IPO | -99.10% |
Recent News & Updates
Shareholder Returns
| BOTHE | BE Biotechs | BE Market | |
|---|---|---|---|
| 7D | -6.8% | -1.1% | -0.8% |
| 1Y | -90.0% | -11.1% | -4.3% |
Return vs Industry: BOTHE underperformed the Belgian Biotechs industry which returned -22.9% over the past year.
Return vs Market: BOTHE underperformed the Belgian Market which returned -16% over the past year.
Price Volatility
| BOTHE volatility | |
|---|---|
| BOTHE Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in BE Market | 7.7% |
| 10% least volatile stocks in BE Market | 2.5% |
Stable Share Price: BOTHE's share price has been volatile over the past 3 months.
Volatility Over Time: BOTHE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 20 | Miguel Forte | www.bonetherapeutics.com |
Bone Therapeutics SA, a biotechnology company, engages in the development of cell therapy products for orthopedics and bone diseases. Its products include ALLOB, an allogeneic cell therapy product, which is in Phase I/IIa clinical trial for the treatment of delayed-union fractures and lumbar spinal fusion; and JTA-004, an intra-articular injectable that is in phase III clinical trial to treat osteoarthritic pain in the knee. Bone Therapeutics SA was incorporated in 2006 and is based in Mont-Saint-Guibert, Belgium.
Bone Therapeutics SA Fundamentals Summary
| BOTHE fundamental statistics | |
|---|---|
| Market cap | €3.42m |
| Earnings (TTM) | -€10.07m |
| Revenue (TTM) | €1.93m |
1.8x
P/S Ratio-0.3x
P/E RatioIs BOTHE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOTHE income statement (TTM) | |
|---|---|
| Revenue | €1.93m |
| Cost of Revenue | €0 |
| Gross Profit | €1.93m |
| Other Expenses | €12.00m |
| Earnings | -€10.07m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Oct 25, 2022
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 100.00% |
| Net Profit Margin | -521.82% |
| Debt/Equity Ratio | -194.0% |
How did BOTHE perform over the long term?
See historical performance and comparison